Management of AIDS-related Kaposi's sarcoma

Summary The advent of highly active antiretroviral therapy (HAART) has lead to a substantial reduction in the prevalence, morbidity, and mortality associated with AIDS-related Kaposi's sarcoma. Similarly, concomitant advances in chemotherapy and supportive-care protocols have allowed for Kaposi...

Full description

Saved in:
Bibliographic Details
Published in:The lancet oncology 2007-02, Vol.8 (2), p.167-176
Main Authors: Di Lorenzo, Giuseppe, Konstantinopoulos, Panagiotis A, MD, Pantanowitz, Liron, MD, Di Trolio, Rossella, MD, De Placido, Sabino, Prof, Dezube, Bruce J, Dr
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
Acquired Immunodeficiency Syndrome - drug therapy
Acquired Immunodeficiency Syndrome - virology
AIDS
Antineoplastic Agents - therapeutic use
Antiretroviral Therapy, Highly Active
Chemotherapy
Drug therapy
Hematology, Oncology and Palliative Medicine
Herpes viruses
HIV
Human immunodeficiency virus
Humans
Kaposis sarcoma
Medical prognosis
Morbidity
Mortality
Sarcoma, Kaposi - drug therapy
Sarcoma, Kaposi - virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary The advent of highly active antiretroviral therapy (HAART) has lead to a substantial reduction in the prevalence, morbidity, and mortality associated with AIDS-related Kaposi's sarcoma. Similarly, concomitant advances in chemotherapy and supportive-care protocols have allowed for Kaposi's sarcoma to be managed more effectively in comparison with the pre-HAART era. Furthermore, developments in our understanding of the pathogenesis of Kaposi's sarcoma have identified several molecular targets that can potentially provide new therapeutic strategies. This Review discusses the role of conventional chemotherapeutic and immunomodulatory agents in the treatment of Kaposi's sarcoma and summarises the current status and future prospects of novel molecularly targeted agents in the treatment of this disease.
ISSN:1470-2045
1474-5488
DOI:10.1016/S1470-2045(07)70036-0